About the Authors
- David Aviezer
-
Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel
- Einat Brill-Almon
-
Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel
- Yoseph Shaaltiel
-
Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel
- Sharon Hashmueli
-
Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel
- Daniel Bartfeld
-
Affiliation Protalix Biotherapeutics, Science Park, Carmiel, Israel
- Sarah Mizrachi
-
Affiliation Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel
- Yael Liberman
-
Affiliation Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel
- Arnold Freeman
-
Affiliation Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel
- Ari Zimran
-
Affiliation Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel
- Eithan Galun
-
* E-mail: eithang@hadassah.org.il
Affiliation Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Hospital, Jerusalem, Israel
Competing Interests
David Aviezer, Einat Brill-Almon, Yoseph Shaaltiel, Sharon Hashmueli, and Daniel Bartfeld are all employed by Protalix (http://www.protalix.com) the company which sponsored the study and also hold the license for the product. As such holds shares in the company. As aponsors and funders of the study Protalix employees (listed above) had a role in study design and review of data analysis. Eithan Galun was an adviser to Protalix. Ari Zimran is a paid consultant of Protalix. All other authors declare no competing financial interests.
Author Contributions
Conceived and designed the experiments: DA EBA AZ EG. Performed the experiments: SM YL AF EG. Analyzed the data: DA EBA SH AZ EG. Contributed reagents/materials/analysis tools: EBA YS SH DB EG. Wrote the paper: DA SH AZ EG.